Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Olena Barbash"'
Autor:
Tatiana Erazo, Chiara M. Evans, Daniel Zakheim, Karen L. Chu, Alice Yunsi Refermat, Zahra Asgari, Xuejing Yang, Mariana Da Silva Ferreira, Sanjoy Mehta, Marco Vincenzo Russo, Andrea Knezevic, Xi-Ping Zhang, Zhengming Chen, Myles Fennell, Ralph Garippa, Venkatraman Seshan, Elisa de Stanchina, Olena Barbash, Connie Lee Batlevi, Christina S. Leslie, Ari M. Melnick, Anas Younes, Michael G. Kharas
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-18 (2022)
Inhibition of the protein arginine methyltransferase PRMT5 has been suggested as a promising therapy for lymphoma. Here, the authors show that TP53 loss of function and MUSASHI-2 (MSI2) expression are biomarkers of resistance to PRMT5-targeted therap
Externí odkaz:
https://doaj.org/article/ae7897107ec04e2091ae2adabb8a333a
624 Targeting Type I arginine methyltransferases promotes T cell mediated antitumor immune responses
Autor:
Guangchun Han, Linghua Wang, Patrick Hwu, Weiyi Peng, Chunyu Xu, Shane O’Brien, Yunfei Wang, Jiakai Hou, Leilei Shi, Leila Williams, Andrew Fedoriw, Kimberly Smitheman, Christian Sherk, Satyajit Rajapurkar, Jenny Laraio, Qin Feng, Mark Bedford, Olena Barbash, Ryan Kruger, Helai Mohammad
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/7e0d9df8f9ea41cc8d766b81b113681a
Autor:
Charles C. Bell, Katie A. Fennell, Yih-Chih Chan, Florian Rambow, Miriam M. Yeung, Dane Vassiliadis, Luis Lara, Paul Yeh, Luciano G. Martelotto, Aljosja Rogiers, Brandon E. Kremer, Olena Barbash, Helai P. Mohammad, Timothy M. Johanson, Marian L. Burr, Arindam Dhar, Natalie Karpinich, Luyi Tian, Dean S. Tyler, Laura MacPherson, Junwei Shi, Nathan Pinnawala, Chun Yew Fong, Anthony T. Papenfuss, Sean M. Grimmond, Sarah-Jane Dawson, Rhys S. Allan, Ryan G. Kruger, Christopher R. Vakoc, David L. Goode, Shalin H. Naik, Omer Gilan, Enid Y. N. Lam, Jean-Christophe Marine, Rab K. Prinjha, Mark A. Dawson
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
There is increasing evidence that epigenetic mechanisms contribute to therapeutic resistance in cancer. Here the authors study AML patient samples and a mouse model of non-genetic resistance and find that transcriptional plasticity drives stable epig
Externí odkaz:
https://doaj.org/article/afef38c61db14a30844be963ce6499a0
Autor:
Kelly Chiang, Agnieszka E. Zielinska, Abeer M. Shaaban, Maria Pilar Sanchez-Bailon, James Jarrold, Thomas L. Clarke, Jingxian Zhang, Adele Francis, Louise J. Jones, Sally Smith, Olena Barbash, Ernesto Guccione, Gillian Farnie, Matthew J. Smalley, Clare C. Davies
Publikováno v:
Cell Reports, Vol 21, Iss 12, Pp 3498-3513 (2017)
Summary: Breast cancer progression, treatment resistance, and relapse are thought to originate from a small population of tumor cells, breast cancer stem cells (BCSCs). Identification of factors critical for BCSC function is therefore vital for the d
Externí odkaz:
https://doaj.org/article/c87094c1b9fa49f294c1e88bb72d1739
Autor:
Anastasia Wyce, Gopinath Ganji, Kimberly N Smitheman, Chun-Wa Chung, Susan Korenchuk, Yuchen Bai, Olena Barbash, BaoChau Le, Peter D Craggs, Michael T McCabe, Karen M Kennedy-Wilson, Lydia V Sanchez, Romain L Gosmini, Nigel Parr, Charles F McHugh, Dashyant Dhanak, Rab K Prinjha, Kurt R Auger, Peter J Tummino
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e72967 (2013)
BET family proteins are epigenetic regulators known to control expression of genes involved in cell growth and oncogenesis. Selective inhibitors of BET proteins exhibit potent anti-proliferative activity in a number of hematologic cancer models, in p
Externí odkaz:
https://doaj.org/article/edc29a7e49b54f8688b20ca3340035d5
Autor:
Weiyi Peng, Helai P. Mohammad, Patrick Hwu, Ryan G. Kruger, Olena Barbash, Linghua Wang, Mark T. Bedford, Qin Feng, Guangchun Han, Chunyu Xu, Leila J. Williams, Jenny Laraio, Satyajit Rajapurkar, Christian Sherk, Jiakai Hou, Yunfei Wang, Kimberly N. Smitheman, Shane O'Brien, Leilei Shi, Andrew Fedoriw
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af6dfa5fcb5450c54402a7d5bd6933d1
https://doi.org/10.1158/2326-6066.22544108
https://doi.org/10.1158/2326-6066.22544108
Autor:
Weiyi Peng, Helai P. Mohammad, Patrick Hwu, Ryan G. Kruger, Olena Barbash, Linghua Wang, Mark T. Bedford, Qin Feng, Guangchun Han, Chunyu Xu, Leila J. Williams, Jenny Laraio, Satyajit Rajapurkar, Christian Sherk, Jiakai Hou, Yunfei Wang, Kimberly N. Smitheman, Shane O'Brien, Leilei Shi, Andrew Fedoriw
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23581ebfc323465362b79ff448ebda54
https://doi.org/10.1158/2326-6066.22544105
https://doi.org/10.1158/2326-6066.22544105
Autor:
Weiyi Peng, Helai P. Mohammad, Patrick Hwu, Ryan G. Kruger, Olena Barbash, Linghua Wang, Mark T. Bedford, Qin Feng, Guangchun Han, Chunyu Xu, Leila J. Williams, Jenny Laraio, Satyajit Rajapurkar, Christian Sherk, Jiakai Hou, Yunfei Wang, Kimberly N. Smitheman, Shane O'Brien, Leilei Shi, Andrew Fedoriw
Protein arginine methyltransferases (PRMT) are a widely expressed class of enzymes responsible for catalyzing arginine methylation on numerous protein substrates. Among them, type I PRMTs are responsible for generating asymmetric dimethylarginine. By
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6012567a496d1caf29d286b0c6d25ca5
https://doi.org/10.1158/2326-6066.c.6550529.v1
https://doi.org/10.1158/2326-6066.c.6550529.v1
Autor:
Michael Dickinson, Brandon E. Kremer, Arindam Dhar, Thierry Horner, Shawn W. Foley, Michael T. McCabe, Natalie O. Karpinich, Geraldine Ferron-Brady, Evi Bakirtzi, Olena Barbash, Anu Shilpa Krishnatry, Anastasia Wyce, Paolo Gallipoli, Ludovica Marando, Faisal Basheer, Regina García Delgado, Paul Yeh, Natalia Tovar, Maria-Victoria Mateos, Manali Kamdar, Jacob L. Glass, Gareth J. Morgan, Faith E. Davies, Daniel A. Pollyea, Dan T. Vogl, Aristeidis Chaidos, Adrian Alegre, Anastasios Karadimitris, Brian J.P. Huntly, Gautam Borthakur, Mark A. Dawson
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::634832d4a4352226ded7a6d727fa619e
https://doi.org/10.1158/1078-0432.22490779
https://doi.org/10.1158/1078-0432.22490779
Autor:
Michael Dickinson, Brandon E. Kremer, Arindam Dhar, Thierry Horner, Shawn W. Foley, Michael T. McCabe, Natalie O. Karpinich, Geraldine Ferron-Brady, Evi Bakirtzi, Olena Barbash, Anu Shilpa Krishnatry, Anastasia Wyce, Paolo Gallipoli, Ludovica Marando, Faisal Basheer, Regina García Delgado, Paul Yeh, Natalia Tovar, Maria-Victoria Mateos, Manali Kamdar, Jacob L. Glass, Gareth J. Morgan, Faith E. Davies, Daniel A. Pollyea, Dan T. Vogl, Aristeidis Chaidos, Adrian Alegre, Anastasios Karadimitris, Brian J.P. Huntly, Gautam Borthakur, Mark A. Dawson
Purpose:Molibresib is a selective, small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. This was an open-label, two-part, Phase I/II study investigating molibresib monotherapy for the treatment of hematological maligna
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b56a0a4932aa41df4a01b11e3217650
https://doi.org/10.1158/1078-0432.c.6533218.v1
https://doi.org/10.1158/1078-0432.c.6533218.v1